Form 4: DiaMedica Therapeutics CFO Granted Significant Stock Options, Aligning Executive Incentives

DiaMedica Therapeutics Inc.'s CFO and Secretary, Scott Kellen, was granted 225,000 stock options with an exercise price of $4.11, alongside his existing direct ownership of 32,290 common shares.

Summary

• Scott Kellen, the Chief Financial Officer and Secretary of DiaMedica Therapeutics Inc. (DMAC), reported changes in his beneficial ownership.
• Mr. Kellen directly owns 32,290 Voting Common Shares, which have no par value per share.
• On June 1, 2025, Mr. Kellen was granted 225,000 stock options, representing a right to buy common shares.
• The exercise price for these newly granted stock options is $4.11 per share.
• The stock options have an expiration date of May 31, 2035.
• The vesting schedule for these options is structured such that 25% of the underlying common shares will vest on June 1, 2026.
• The remaining 75% of the underlying common shares will vest quarterly over the subsequent three years, commencing on September 1, 2026.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive like the CFO is generally viewed positively as it aligns management's financial interests with the long-term performance of the company and shareholder value. It signals confidence in the company's future prospects from an insider's perspective.

Positives

• The grant of 225,000 stock options to the CFO aligns management's financial interests with the long-term performance of the company and shareholder value.
• The significant option grant indicates a commitment to retaining key executive talent and incentivizing future performance.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not provide forward-looking statements regarding the company's financial performance or strategic guidance. However, the grant of stock options indicates a future potential for the CFO to acquire additional shares, aligning his long-term financial interests with the company's success.

Management Comments

• Scott Kellen, CFO & Secretary, was granted 225,000 stock options, aligning his incentives with long-term shareholder value.

Industry Context

The grant of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, as well as across many other sectors, to incentivize performance, retain talent, and align management's interests with those of shareholders. This filing reflects a routine aspect of executive compensation within DiaMedica Therapeutics.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation across the biotech and pharmaceutical industries, used to incentivize long-term performance and align executive interests with shareholder value.
• The specific size of the grant (225,000 options) and the exercise price ($4.11) would typically be evaluated against compensation packages for CFOs at peer companies of similar market capitalization, stage of development, and industry segment (e.g., clinical-stage biotech firms focused on neurological disorders or kidney disease).
• The vesting schedule (25% after one year, then quarterly over three years) is a standard practice designed to encourage long-term commitment and performance, comparable to typical equity incentive plans seen at companies like Biogen Inc. or Vertex Pharmaceuticals Inc. for their executive teams, though the specific numbers would differ based on company size and executive role.

Stakeholder Impact

• Shareholders: The grant of stock options can be seen as a positive signal of management's long-term commitment and incentive alignment, potentially leading to increased shareholder value if the company performs well. However, future exercise of options could lead to minor dilution.
• Employees: No direct impact on general employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Vesting of 25% of the granted stock options on June 1, 2026.
• Commencement of quarterly vesting for the remaining 75% of the stock options on September 1, 2026.
• Potential exercise of vested stock options by Scott Kellen at any point before the expiration date of May 31, 2035.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Scott Kellen, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership